{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202881","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.352866+00:00","generated_at":"2026-06-12T09:10:20.426311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvation Bio Q2 net loss narrows to $20.6M; cash $630.9M; NUV-868 studies enrolling","bullets":["Net loss of $20.6M ($0.09/share) vs $34.9M ($0.16/share) in Q2 2022.","Cash, cash equivalents and marketable securities of $630.9M as of June 30, 2023.","R&D expenses decreased to $18.6M from $28.9M, partly due to NUV-422 program termination.","Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy enrolling.","Expects to submit IND for first DDC candidate by year end 2023; formed Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202881","json":"https://secwatch.observer/filing/0001193125-23-202881.json","markdown":"https://secwatch.observer/filing/0001193125-23-202881.md","text":"https://secwatch.observer/filing/0001193125-23-202881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/0001193125-23-202881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/d517241d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:10:20.426311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}